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Abstract 
Recombinant activated coagulation factor VII (rFVIIa) is known to be effective in the 
management of acquired deficiencies of factor VII and platelet function defects. But 
recently, rFVIIa has been successfully used to treat ongoing bleeding in disseminated 
intravascular coagulopathy (DIC) condition. The patient reported here was suspected to 
be suffering from toxic hepatitis on admission. After percutaneous liver biopsy, bleeding 
occurred and did not stop even after right hepatic artery embolization. The patient 
developed a severe hemorrhage that resulted in hypovolemic shock, hemoperitoneum, 
and a massive subcapsular hematoma. The patient then developed DIC due to massive 
transfusion, as well as acute liver necrosis. The patient was given 400 μg/kg of rFVIIa. 
Recombinant factor VIIa was administered in an attempt to control the bleeding. This 
stabilized the hemoglobin levels of the patient. The patient gradually recovered in 4 
months. In conclusion, this case suggests that rFVIIa can be successfully used for the 
hemostasis of uncontrolled bleeding in DIC. 
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Introduction 
Although recombinant factor VII activated form (rFVIIa; NovoSeven, Novo Nordisk 
A/S, Bagsvaerd, Denmark) was initially developed for the treatment of bleeding associated 
with inhibitors to factor VII and IX, most recently it has been used effectively in the 
management of acquired deficiencies of factor VII and platelet function defects. A cell-
based model of hemostasis can explain why it can work in the disseminated intravascular 
coagulopathy (DIC) condition [1]. 
The worst complication of liver biopsy is bleeding. While this complication resolves 
spontaneously in a normal hemostatic condition in most cases [1], massive subcapsular 
hematoma of the liver can occur after percutaneous transhepatic liver biopsy [2]. Such 
hematomas are usually more commonly seen after major blunt trauma or liver 
transplantation [3, 4] or in amyloidosis patients [5]. 
We recently treated a patient who was admitted because of alleged toxic hepatitis. She 
was subsequently suspected to have an autoimmune hepatitis. To differentiate between 
these two disease conditions, we performed a percutaneous liver biopsy. As a 
consequence, the patient suffered continuous bleeding for 4 days and a subcapsular 
hematoma developed. We report here that this complication was successfully managed by 
using rFVIIa. 
Case Report 
A 40-year-old woman presented to our medical center with the chief complaint of jaundice. The 
patient felt weakness, loss of appetite, and nausea. The patient had drunk an extract made by boiling 
down arrowroot for 1 month. Her medical history only revealed a 2-year history of hypertension. There 
was no family history of hepatobiliary disease. Apart from her jaundice, the patient’s physical 
examination was unremarkable. Her vitals were as follows: blood pressure, 100/80 mm Hg; heart rate, 
80/min; respiratory rate, 20/min; body temperature, 36.5°C. Complete blood count (CBC) revealed 
white blood cell (WBC) counts of 8,790/μl, hemoglobin (Hb) levels of 12.9 g/dl, and platelet counts of 
284 × 10
3/μl. Liver function test results revealed AST levels of 765 IU/l, ALT levels of 463 IU/l, alkaline 
phosphatase levels of 248 IU/l, total bilirubin levels of 20.1 mg/dl, and direct bilirubin levels of 15.2 
mg/dl. The patient was treated conservatively with hydration for a week, and her laboratory results 
improved to AST levels of 462 IU/l, ALT levels of 358 IU/l, and total bilirubin levels of 7.4 mg/dl. 
However, since the patient had weakly positive serum anti-nuclear antibody levels (1:80), we decided to 
conduct an ultrasonography-guided percutaneous liver biopsy to differentiate autoimmune hepatitis 
from toxic hepatitis.  
On the ninth day in hospital, the liver biopsy was performed at 1:00 p.m. We marked the biopsy site 
on the skin during ultrasonography and shot an 18-gauge spring-loaded liver biopsy needle (Angiomed 
Autovac biopsy needle; Bard, Karlsruhe, Germany) at the biopsy site twice. On the first shot, we 
obtained a 0.7 cm-sized tissue piece and the patient did not complain of any symptoms. On the second 
shot, a 3 cm-sized liver tissue was obtained. The patient then complained that she felt a twinge-like pain 
in her right chest that radiated into the right shoulder. The patient also reported light dyspnea. 
Analgesics were administered, after which the pain and dyspnea gradually subsided. At that time, the 
patient’s vitals were stable and further sequelae were not expected. On the same day, at 11:30 p.m., the 
patient complained of dizziness and abdominal distension. She then became confused and lost 
consciousness. Her systolic blood pressure was 80 mm Hg and diagnostic paracentesis revealed bloody 
ascites. We suspected the patient was suffering from hemorrhagic shock due to bleeding from an 
iatrogenic liver injury. Abdominal CT showed that the right lobe of the liver was severely compressed by 
a huge subcapsular hematoma (fig. 1). Packed red blood cells (RBCs) and crystalloid were administered 
and inotrophics were infused. At the same time, an emergency angiography was performed which 
revealed that the bleeding came from the right hepatic artery. Consequently, we embolized the culprit 
vessel by intravascular coiling. The patient’s blood pressure remained relatively stable after the 
procedure, but began to fall when we tried to taper off the dose of inotrophics. A second angiogram 
obtained on the tenth day in hospital showed no evidence of arterial bleeding.   
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The patient was admitted to the intensive care unit (ICU). Despite being transfused with 10, 3, 3, and 
2 units of packed RBC on days 10, 11, 12, and 13, respectively, the patient’s hemoglobin levels gradually 
decreased from 13.1 to 8.8 g/dl. In total, 18 units (4,500 ml) of packed RBC were transfused prior to the 
infusion of rFVIIa. On the eleventh day in hospital, the patient was given 500,000 units of aprotinin 
(Rotinin inj; Han Lim Pharm, Seoul, Korea) over 15 min as the loading dose, after which 200,000 units 
were infused continuously each hour for 5 h as the maintenance dose. Despite the injection of aprotinin, 
the patient’s hemoglobin levels decreased persistently. On the twelfth day in hospital, the patient was 
given 2.4 mg (40 μg/kg) of rFVIIa 4 times every 2 hours, and then 4.8 mg (80 μg/kg) 3 times every 2 
hours. On day 13, the blood pressure and hemoglobin levels of the patient stabilized in the absence of 
transfusion (fig. 2). On day 13, the patient’s laboratory results revealed that her prothrombin time was 
20.7 s (INR 2.03), her activated partial thromboplastin time was 82.0 s, her fibrin degradation product 
level was 17.5 μg/ml, and her D-dimer level was 6,245 ng/ml. The patient was treated in the ICU for 2 
months because of the intra-abdominal and the intrathoracic hematoma and its complications, namely 
DIC due to massive transfusion, acute renal failure, acute respiratory failure, and liver failure due to 
liver necrosis.  
The patient recovered gradually from these complications in terms of liver injury and jaundice 
(fig. 3) and was discharged 4 months after her admission. A follow-up CT scan showed a considerable 
reduction in the size of the subcapsular hematoma. The results of the liver biopsy were compatible with 
toxic hepatitis, but we remained unable to exclude autoimmune hepatitis completely. 
Discussion 
We describe here a patient with subcapsular hematoma that developed after 
percutaneous liver biopsy. To obtain hemostasis, we attempted embolization of the right 
hepatic artery and intravenous injections with aprotinin. These methods failed to stem the 
gradual decrease in hemoglobin levels that persisted despite the transfusion of large 
amounts of packed RBCs. Finally, four 40 μg/kg doses and three 80 μg/kg doses of rFVIIa 
were administered intravenously. Ten hours later, the hemoglobin levels stabilized in the 
absence of further transfusion. 
Clinically significant intraperitoneal hemorrhage is the most serious bleeding 
complication of percutaneous liver biopsy [1]. The mortality rate among patients after 
percutaneous liver biopsy is approximately 1 in 10,000 to 1 in 12,000 [1, 6]. The mortality 
rate is highest among patients who undergo biopsies of malignant lesions. Cirrhosis is 
another risk factor for fatal bleeding after liver biopsy. 
Two cases of subcapsular hematoma have been reported, one in a patient receiving a 
liver graft and the other in a patient with cholestatic liver disease. The present case had 
severe cholestasis associated with toxic hepatitis, but no underlying chronic liver disease 
[3, 7]. 
If hemorrhage is suspected, the administration of IV fluids and blood products should 
be performed immediately to improve the patient’s hemodynamic status, and a surgeon 
and an angiographer should be kept on standby. If hemodynamic instability persists for a 
few hours despite the use of aggressive resuscitative measures, angiography and 
embolization or surgical exploration are indicated [2]. It is generally believed that timely 
percutaneous external drainage of the large hematoma is needed to prevent the 
compression of functioning hepatocytes, which may harm the liver, although some 
authors insist that it may remove the tamponade effect of the hematoma on the bleeding 
focus [3]. We frequently performed paracentesis after confirming complete hemostasis 
from the liver. 
While rFVIIa was developed to manage bleeding in hemophiliac patients who express 
inhibitors of clotting factors, it was unclear why rFVIIa but not endogenous FVII could 
overcome coagulopathy in hemophiliac patients. A cell-based conceptual model of  
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hemostasis that focuses on the roles of specific cell surfaces in controlling the coagulation 
process may shed light on this phenomenon. FVIIa can bind to activated platelets and, 
once bound to the activated platelet surface, can activate factor X. The cell-based model 
suggests that while the low levels of endogenous FVIIa cannot induce thrombin 
generation on the platelet surface, when rFVIIa is added to the system, thereby elevating 
the total FVIIa levels, the thrombin-generating function of the platelet surface can be 
restored [8]. In the present case, rFVIIa was administered after we identified and 
embolized the bleeding focus in the course of right hepatic artery because the bleeding did 
not stop, even though there was no obvious bleeding point after embolization, as 
indicated by the second angiography. After administration of rFVIIa, there was no 
evidence of further bleedings. Thus, we can presume that the administration of rFVIIa 
successfully controlled the undisclosed bleeding from the site where the biopsy was 
performed. 
Which dose of rFVIIa is appropriate for a bleeding patient who does not have 
deficiency of coagulation factor VII? One study showed that when patients with chronic 
liver disease are given 80 μg/kg rVIIa prior to surgical incision during orthotopic liver 
transplantation, it is both safe and effective [9]. Another study showed that the decline in 
hematocrit during an operation undergoing liver resection was smallest in the group 
receiving 80 μg/kg of rFVIIa, and that this was associated with a significant overall 
improved effect of treatment [10]. In our patient, we administered a half dose of rFVIIa 3 
times on the twelfth day. On the thirteenth day in hospital, we administered the full dose 
of rFVIIa 3 times because the half dose was suboptimal for hemostasis, totaling 400 μg/kg. 
rFVIIa is effective for hemostasis not only in hemophiliac patients [11], but also in 
patients with thrombocytopathies [12], liver transplantation [9, 13], and hemophiliac 
patients undergoing orthopedic surgery [14]. We would like to report the successful use 
of rFVIIa in a DIC patient with potentially fatal iatrogenic bleeding. We also suggest that 
DIC should be omitted from the contraindication list of rFVIIa use. 
 
 
 
 
 
Fig. 1. The presence of a subcapsular hematoma is shown on the pre-enhanced image (left), while 
massive hepatic necrosis is revealed by the post-enhanced image (right). 
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Fig. 2. Blood pressure (BP) and hemoglobin (Hb) profiles of the patient before and after rFVIIa 
administration. PRC = Infusion of packed red blood cells. The hemoglobin level was stable after rFVIIa 
without PRC transfusion. 
 
 
 
Fig. 3. Serum ALT and bilirubin profiles during hospitalization. After skyrocket increase of ALT and 
total bilirubin due to right lobe infarct, the ALT and total bilirubin became normal 3 months after liver 
biopsy. 
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